Incyte, Hengrui In ‘Biggest Ever’ China Pharma Out-Licensing Deal
This article was originally published in PharmAsia News
Incyte has acquired most global rights to an immuno-oncology antibody developed by China's Jiangsu Hengrui, in a deal worth up to nearly $800m plus royalties that will give the US firm a foothold in the PD-1 area and open up new combination therapies.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context